Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hakan Paydak

Clinical Cardiac Electrophysiology Little Rock, AR Medical Doctor

NPI 1871547828 CMS profile 673272

4301 W Markham St # 532, Ste 2H, Little Rock, AR 72205

Open in the dashboard

General payments

$2,432

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hakan Paydak of Little Rock, AR is reported in the CMS Open Payments database as having received $2,432 across 44 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 13th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $338 12
2024 General $332 10
2023 General $320 7
2022 General $183 5
2020 General $105 2
2019 General $1,154 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hakan Paydak
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Hakan Paydak were reported at $338. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Hakan Paydak Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,154 $2,361 $585–$8,260 $163
2020 $105 $993 $247–$4,351 $114
2021 $0 $1,185 $326–$4,739 $132
2022 $183 $2,073 $554–$6,789 $149
2023 $320 $2,568 $759–$8,159 $160
2024 $332 $2,557 $703–$7,403 $164
2025 $338 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,606 19 payments
  2. Medtronic, Inc. $377 11 payments
  3. Boston Scientific Corporation $321 7 payments
  4. Biotronik Inc. $28 1 payment
  5. Philips Electronics North America Corporation $23 1 payment
  6. Cardiva Medical, Inc. $18 1 payment
  7. Shockwave Medical, Inc $18 1 payment
  8. Edwards Lifesciences Corporation $16 1 payment
  9. Medtronic Vascular, Inc. $14 1 payment
  10. Biosense Webster, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,345 40 payments
  2. Travel and Lodging $1,087 4 payments
Products named General payments · program years 2019–2025
  1. Cardiac Mapping System $1,081 4 payments
  2. AURORA EV-ICD MRI SURESCAN $241 5 payments
  3. ENSITE PRECISION $107 1 payment
  4. WATCHMAN $105 2 payments
  5. MITRACLIP $86 4 payments
  6. ENSITE $74 1 payment
  7. Micra $69 3 payments
  8. TACTICATH ABLATION CATHETER, SENSOR ENABLED $68 1 payment
  9. DxTerity $41 2 payments
  10. AGILIS $41 1 payment
  11. Other $347 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,581

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$487,477

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

30.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 263 $262,882
Xarelto Rivaroxaban Brand 59 $65,108
Multaq Dronedarone Hcl Brand 34 $44,050
Entresto Sacubitril/Valsartan Brand 30 $41,109
Jardiance Empagliflozin Brand 21 $31,809
Flecainide Acetate Generic 181 $9,023
Metoprolol Succinate Generic 188 $3,497
Nifedipine Er Nifedipine Brand 108 $2,965
Potassium Chloride Generic 110 $2,933
Amiodarone Hcl Generic 97 $2,428

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$70,407

Medicare's payments for the services billed

Medicare patients

1,386

Average age 72

Services billed

2,467

714 women, 672 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 46%
Chronic kidney disease 42%
Heart failure 41%
Atrial fibrillation 41%
Diabetes 39%
Depression 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record